Nymox Pharmaceutical (NYMX) Receiving Somewhat Favorable News Coverage, Report Shows

News headlines about Nymox Pharmaceutical (NASDAQ:NYMX) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.2096869786036 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Separately, ValuEngine raised shares of Nymox Pharmaceutical from a “sell” rating to a “hold” rating in a report on Friday, August 11th.

Nymox Pharmaceutical (NASDAQ NYMX) traded down $0.08 during mid-day trading on Monday, hitting $3.69. 40,000 shares of the company were exchanged, compared to its average volume of 161,609. Nymox Pharmaceutical has a 1 year low of $2.67 and a 1 year high of $5.10. The company has a quick ratio of 1.42, a current ratio of 1.44 and a debt-to-equity ratio of 61.64.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/nymox-pharmaceutical-nymx-receiving-somewhat-favorable-news-coverage-report-shows.html.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply